This week’s Newsmaker is Mike Betel, Founder of the Fatty Liver Alliance. He discusses some of the reasons that key MASLD Patient Advocates like himself are getting more visibility at a broader swath of global conferences and the messages he delivers at the conferences he attends.
This concluding segment of the Emerging Trends Conference 2025 Roundtable expresses optimism about the future for Steatotic Liver Disease patients, with a better understanding of how to treat based on viewing steatotic liver disease as a spectrum and an accompanying explosion of the number and diversity of drugs available to treat patients with MASLD, MetALD and ALD.
SurfingMASH concludes its coverage of the Emerging Trends Conference looking at an encouraging future in MASLD drug development and increasing interest in patient advocacy.
This week’s Roundtable segment focuses on what we can learn from today’s trial results about trends for the future and asks questions about ALD trial design.
SurfingMASH explores the future evolution of drug therapy, a new biopsy-enhancing option for clinical use and the implications of FDA and NIH job cuts.
This final conversation focuses on conference presentations on Determinants of MASH Health and the Healthy Livers, Healthy Lives program, and what panelists anticipate for #TLM2025.
This conversation focuses on two patient-related issues: the importance of patient advocacy in removing biopsy from clinical trial designs and more generally, principles for patient-centric clinical trials.
This conversation covers the likely role of FGF-21 agents in future MASH therapy and discusses positive messages from the “FDA Corner” session.
This conversation starts by asking whether approval of two drugs for use without biopsy will challenge MASH trial recruitment and goes on to look at recent studies discussing patient genotyping and clustering.
In the first conversation of our review of #TLM2024, panelists share general impressions and discuss the ESSENCE trial, semaglutide’s Phase 3 trial demonstrating regression of fibrosis.
